Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
Express Scripts
McKesson

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

HUMIRA Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for HUMIRA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesPhase 4
Wake Forest University Health SciencesPhase 4
Fundación Pública Andaluza para la gestión de la Investigación en SevillaPhase 4

See all HUMIRA clinical trials

Recent Litigation for HUMIRA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Coherus Biosciences, Inc. v. Amgen Inc.2019-01-24
ABBVIE INC. v. SANDOZ INC.2018-08-10
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06

See all HUMIRA litigation

PTAB Litigation
PetitionerDate
Fresenius Kabi USA, LLC2019-09-17
2017-11-06
2017-10-02

See all HUMIRA litigation

Pharmacology for HUMIRA

Patent Text Search: US Patents for HUMIRA

These patents were identified by searching patent claims

Supplementary Protection Certificates for HUMIRA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CR 2015 00021 Denmark   Start Trial PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141023
15C0029 France   Start Trial PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023
CR 2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
233 5006-2015 Slovakia   Start Trial PRODUCT NAME: IBRUTINIB; REGISTRATION NO/DATE: EU/1/14/945 20141023
CA 2017 00012 Denmark   Start Trial PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707
CA 2016 00056 Denmark   Start Trial PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2016)3293 20160530
PA2017009 Lithuania   Start Trial PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2015)4704 20170703
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Express Scripts
Baxter
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.